Questioning Conclusions and Statements on the German HTA System: A Critical Perspective
Clin Pharmacol Ther
.
2025 Jan;117(1):22-23.
doi: 10.1002/cpt.3296.
Epub 2024 May 9.
Authors
Jörg Tomeczkowski
1
,
Tanja Heidbrede
2
,
Friedhelm Leverkus
3
,
Sarah Schmitter
3
,
Charalabos-Markos Dintsios
4
,
Ulrike Osowski
5
,
Kirsten H Herrmann
6
,
Tobias Bluhmki
7
,
Almuth Marx
8
,
Birte Eichinger
8
,
Edin Basic
9
,
Paul Bussilliat
10
,
Eva Susanne Dietrich
1
Affiliations
1
Institute for Evidence-Based Positioning in the Health Care Sector at the University of Bonn, Bonn, Germany.
2
UCB BioSciences, Monheim, Germany.
3
Pfizer Pharma, Berlin, Germany.
4
Institute for Health Services Research and Health Economics, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
5
Merck Healthcare Germany, Darmstadt, Germany.
6
Pharming, Ottobrunn, Germany.
7
Bristol-Myers Squibb, Munich, Germany.
8
Novartis AG, Nuremberg, Germany.
9
Berlin School of Economics and Law, Berlin, Germany.
10
vfa Berlin, Berlin, Germany.
PMID:
38721790
DOI:
10.1002/cpt.3296
No abstract available
Publication types
Letter